Pontifax Management 4 G.P. (2015) Ltd. sold KROS
October 15, 2025 · Form 4 insider transaction
Pontifax Management 4 G.P. (2015) Ltd. sold 1,226,412 shares of Keros Therapeutics, Inc. at $17.75 per share, a transaction worth $21.77M. The trade was recorded as open-market sale and disclosed on an SEC Form 4, filed 2 days after the transaction.
Footnotes
The securities are held by Pontifax (China) IV, L.P. ("China IV"). Management 4 is the ultimate general partner of China IV. As a result, Management 4 may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Tomer Kariv and Ran Nussbaum is a Managing Partner of Management 4 and, as a result, Messrs. Kariv and Nussbaum may be deemed to share voting and investment power with respect to the shares held by China IV. Management 4 and Messrs. Kariv and Nussbaum disclaim beneficial ownership of such shares, except to the extent of his or its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise.